Search Within

Shanu Modi

Formats
  1. Meeting Abstract (150)
  2. Journal Article (99)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (265)
  2. Department of Medicine (265)
  3. Solid Tumor Oncology Division (265)
  4. Survivorship Research (113)
  5. GSK Faculty (104)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (88)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (49)
  4. Sujata Patil (44)
  5. Chau Dang (41)
  6. Komal Jhaveri (34)

More People

Years
  1. 2025 (5)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (265)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting the cyclin d-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective cdk 4/6 inhibitors in hormone receptor-positive breast cancer: Rationale, current status, and future directions
    Journal Article

    Spring, L.; Bardia, A.; Modi, S.
    Discovery Medicine (2016)

    Fulltext@MSK | Save
  • Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy
    Meeting Abstract

    Taldone, T.; Pillarsetty, N.; Dunphy, M. P. S.; Gerecitano, J. F.; Caldas-Lopes, E.; Beattie, B.; Peter, R. I.; Kang, Y. L.; Rodina, A.; Yan, P.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation
    Journal Article

    Yang, T. J.; Morrow, M.; Modi, S.; Zhang, Z.; Krause, K.; Siu, C.; McCormick, B.; Powell, S. N.; Ho, A. Y.
    Annals of Surgical Oncology (2015)

    Fulltext@MSK | Save
  • A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors
    Meeting Abstract

    Juric, D.; Rodon, J.; Bauer, T. M.; Wainberg, Z.; Tolaney, S.; Modi, S.; Martin, A. G.; Hengelage, T.; Melendez, M.; Choudhury, S.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Ganetespib: Research and clinical development
    Journal Article

    Jhaveri, K.; Modi, S.
    OncoTargets and Therapy (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save